Koers GENB AS Other OTC
Aandelen
US3723032062
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 19,8 mld. 2,88 mld. 2,65 mld. | Omzet 2025 * | 23,62 mld. 3,44 mld. 3,16 mld. | Marktkapitalisatie | 132 mld. 19,21 mld. 17,65 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4,68 mld. 682 mln. 627 mln. | Nettowinst (verlies) 2025 * | 6,63 mld. 966 mln. 888 mln. | EV/omzet 2024 * | 5,33 x |
Nettoliquiditeiten 2024 * | 26,36 mld. 3,84 mld. 3,53 mld. | Nettoliquiditeiten 2025 * | 33,63 mld. 4,9 mld. 4,5 mld. | EV/omzet 2025 * | 4,16 x |
K/w-verhouding 2024 * |
29,9
x | K/w-verhouding 2025 * |
21,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,5% |
Recentste transcriptie over GENB AS
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 63 | 01-01-99 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01-01-07 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23-03-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01-01-17 |
Director/Board Member | 73 | 01-11-03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 01-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 114 mld. | |
+11,84% | 104 mld. | |
-14,15% | 22,41 mld. | |
-1,05% | 22,28 mld. | |
-38,29% | 18 mld. | |
-4,16% | 17,89 mld. | |
+7,99% | 14,28 mld. | |
+36,24% | 12,55 mld. | |
-24,95% | 8,45 mld. |